Details

Autor(en) / Beteiligte

• Schwartz, Gregory G
• Olsson, Anders G
• Abt, Markus
• Ballantyne, Christie M
• Barter, Philip J
• Brumm, Jochen
• Chaitman, Bernard R
• Holme, Ingar M
• Kallend, David
• Leiter, Lawrence A
• Leitersdorf, Eran
• McMurray, John J.V
• Mundl, Hardi
• Nicholls, Stephen J
• Shah, Prediman K
• Tardif, Jean-Claude
• Wright, R. Scott

Titel

Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome

Ist Teil von

• The New England journal of medicine, 2012-11, Vol.367 (22), p.2089-2099

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2012

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Dalcetrapib, an inhibitor of cholesteryl ester transfer protein, raises HDL cholesterol levels. In this clinical trial involving patients with an acute coronary syndrome, dalcetrapib had no beneficial effect on clinical outcomes, despite raising HDL cholesterol levels. High-density lipoproteins (HDLs) participate in the process of cellular cholesterol efflux and may have additional protective effects against atherothrombosis. 1 An inverse association between levels of HDL cholesterol and incident events of coronary heart disease has been shown in observational studies 2 , 3 and persists in most post hoc analyses and meta-analyses of trials of statin therapy for patients with cardiovascular risk factors, chronic cardiovascular disease, or recent acute coronary syndrome. 4 – 10 However, it remains uncertain whether pharmacologic intervention that raises HDL cholesterol levels results in decreased cardiovascular risk. 11 – 16 Moreover, changes in HDL cholesterol levels may not reflect changes in the . . .